Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. [electronic resource]
Producer: 20200601Description: 2090-2095 p. digitalISSN:- 1440-1746
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal, Humanized -- adverse effects
- Colitis, Ulcerative -- drug therapy
- Colonoscopy
- Crohn Disease -- drug therapy
- Drug Substitution -- methods
- Female
- Gastrointestinal Agents -- adverse effects
- Humans
- Inflammatory Bowel Diseases -- drug therapy
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Remission Induction
- Retrospective Studies
- Severity of Illness Index
- Treatment Outcome
- Tumor Necrosis Factor Inhibitors -- therapeutic use
- Young Adult
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.